| This week's sponsor is Premier Research. | | | How Psoriasis Treatment Advanced, and What's Next
Thanks to new biologics, more than half of treated psoriasis patients achieve essentially clear skin. Our white paper examines how we got here, and what's next. Premier Research. It's what we do. Best. |
Today's Rundown Sanofi/Regeneron’s ‘breakthrough’ PD-1 hits positive notes in skin cancer Teva to shutter Israeli R&D site in company reorg Provectus CEO siphoned $3M for 'surgeries, restaurant tips and travel' [Sponsored] How Real-World Evidence and Value-Based Contracts Can Help Payers and Manufacturers Find Common Ground in Rare Disease Pionyr Immunotherapeutics gains meaty $62M series B Vernalis, Daiichi form oncology drug discovery collaboration Arrakis bolsters RNA-targeting tech with UPenn license CTI Clinical Trial expands European, Latin American footprints with Eurotrials buy Featured Story | | | Wednesday, December 13, 2017 It may be way back in the race for market share, but Sanofi and Regeneron touted new topline data for their midstage checkpoint inhibitor in a certain form of skin cancer this morning. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Wednesday, December 13, 2017 Teva Pharmaceutical will reveal a restructuring plan on Thursday which includes slashing about half of its Israeli workforce, as well as closing a research and development center. Wednesday, December 13, 2017 The former CEO of Tennessee biotech Provectus treated the company as his “personal piggy bank,” taking millions of dollars from the business, says the SEC. Monday, December 11, 2017 When payers and manufacturers brawl over pricing, patients with rare diseases can suffer. Is there any common ground? Both sides believe real-world evidence can help quantify the benefits of a medication, and value-based contracts can ensure patients reap the rewards. Wednesday, December 13, 2017 California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment. Wednesday, December 13, 2017 Daiichi Sankyo has tapped Vernalis for its drug discovery expertise. The agreement will see Vernalis turn its fragment and structure-based drug discovery platform on undisclosed cancer targets. Wednesday, December 13, 2017 Arrakis Therapeutics has licensed technology from the University of Pennsylvania that enables the targeting of RNA with small molecules. The deal gives Arrakis rights to families of compounds that bind to three-way junctions found in folded RNA. Wednesday, December 13, 2017 Kentucky-based CRO CTI Clinical Trial and Consulting Services will acquire Portuguese counterpart Eurotrials to create a top-20 CRO with a strong global presence in the U.S., Europe, South America and Asia-Pacific. Resources Sponsored by: Seton Hall Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics. Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA BIO CEO & Investor Conference February 12-13, 2018 | New York, New York | 